Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Deciphering the dynamic-plasticity and heterogeneity of cancer-associated fibroblasts

Project description

Reprogramming tumour-supporting cells

Tumours are surrounded by a microenvironment that strongly impacts how cancer develops, spreads and responds to therapy. The microenvironment consists of different supporting cell types. The most prevalent of these, cancer-associated fibroblasts (CAFs), are highly diverse, with some subtypes promoting tumour growth and others inhibiting it. Understanding how this diversity emerges and evolves as cancer progresses is essential for developing more precise and effective treatments. The goal of the ERC-funded DynamHet project is to use patient-derived 3D tumour models to trace the origins of different CAF subtypes and investigate their dynamic interactions. Ultimately, researchers seek to improve cancer outcomes by reprogramming CAFs into therapeutically beneficial cells.

Objective

Cancer-associated fibroblasts (CAFs) are one of the most abundant and versatile cell types in the tumour microenvironment (TME), where they crosstalk with stromal cells and actively participate in tumour development. Because of their assumed pro-tumourigenic functions, CAFs have long been considered an attractive therapeutic target. However, recent evidence indicates that multiple CAF subpopulations showing inflammatory, myofibroblastic, vascular, antigen-presenting, and immunosuppressive phenotypes co-exist within the same tumour, with some promoting and other restricting tumour growth; thus, making their targeting challenging. How CAFs change dynamically as cancers evolve, and how this may affect the overall tumour heterogeneity, remains unaddressed. Therefore, the main goal of DynamHet is to elucidate the origin and evolution of CAF heterogeneity and to decipher the mediators and mechanisms that regulate CAF plasticity as the tumour advances. This is crucial for the development of effective therapies aimed at reprogramming CAFs towards therapeutically favourable phenotypes and will constitute a great breakthrough in the field of oncology. Hence, DynamHet aims to 1) decipher the origin of CAF heterogeneity by performing clonal tracing and by generating and characterising CAF subtypes starting from human induced pluripotent stem cells; 2) dissect CAF-TME crosstalk by generating 3D patient-derived organoids and spheroids and by analysing their secretome and transcriptomic profiles using high throughput technologies and computational analysis; and 3) reprogramme CAFs by genetic manipulation in favour of therapeutically advantageous subpopulations as a novel therapeutic approach. DynamHet is an ambitious and feasible project that stands as a pioneer in the new concept of deciphering the origin and reprogramming the dynamic heterogeneity of CAFs towards the development of innovative precision medicine approaches in cancer.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2022-STG

See all projects funded under this call

Host institution

FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Net EU contribution
€ 1 775 190,00
Address
CARRER ROSSELLO 149
08036 Barcelona
Spain
Region
Este Cataluña Barcelona
Activity type
Research Organisations
Links
Total cost
€ 1 775 190,00

Beneficiaries (1)